|

GSK5764227 Clinical Trials

5 actively recruiting trials across 4 locations

Pipeline

Phase 1: 3Phase 3: 1Phase 1/2: 1

Top Sponsors

  • GlaxoSmithKline5

Indications

  • Cancer5
  • Neoplasms3
  • Lung Cancer2
  • Neoplasms, Lung1
  • Gastrointestinal Neoplasms1

Other1 trial

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Phase 3

Los Alamitos, California1 trial

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

GSK Investigational Site

Phase 1/2

San Francisco, California1 trial

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

GSK Investigational Site

Phase 1

Stanford, California1 trial

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

GSK Investigational Site

Phase 1

Lake Success, New York1 trial

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

GSK Investigational Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.